|
" Melanoma : "
edited by Ernest C. Borden.
| Document Type
|
:
|
BL
|
| Record Number
|
:
|
975957
|
| Doc. No
|
:
|
b730327
|
| Main Entry
|
:
|
Borden, Ernest C.
|
| Title & Author
|
:
|
Melanoma : : Biologically Targeted Therapeutics /\ edited by Ernest C. Borden.
|
| Publication Statement
|
:
|
Totowa, N.J. :: Humana Press,, ©2002.
|
|
|
:
|
Totowa, NJ :: Humana Press :: Imprint :: Humana Press,, 2002.
|
| Series Statement
|
:
|
Current Clinical Oncology
|
| Page. NO
|
:
|
1 online resource (415 pages)
|
| ISBN
|
:
|
128082123X
|
|
|
:
|
: 1468496689
|
|
|
:
|
: 1592591590
|
|
|
:
|
: 6610821232
|
|
|
:
|
: 9781280821233
|
|
|
:
|
: 9781468496680
|
|
|
:
|
: 9781592591596
|
|
|
:
|
: 9786610821235
|
| Bibliographies/Indexes
|
:
|
Includes bibliographical references and index.
|
| Contents
|
:
|
I Perspective on the Clinical Disease -- 1 Management of Primary Malignant Melanoma -- 2 A Pathologist's Perspective on Prognostic Featuresof Malignant Melanoma -- 3 Clinical Prognostic Factors and Staging -- II Biological and Targeted Therapeutics -- 4 Principles of Antitumor Immunity and Tumor-Mediated Immunosuppression -- 5 Immunotherapy of Advanced Melanoma Directed at Specific Antigens -- 6 Melanoma Antigens: Vaccines and Monoclonal Antibodies -- 7 Interleukin-2 -- 8 Interleukin-12: Immunologic and Antitumor Effects in Human Malignant Melanoma -- 9 Interferons: Preclinical and Clinical Studies in Melanoma -- 10 Biochemotherapy of Melanoma -- 11 Signal Transduction Abnormalities as Therapeutic Targets -- 12 Tumor Angiogenesis -- 13 Antiangiogenic Therapy for Melanoma.
|
| Abstract
|
:
|
Substantial progress in the effective prevention and treatment of primary and recurrent melanomas is now being regularly achieved using therapeutic proteins and cells. In Melanoma: Biologically Targeted Therapeutics, Ernest C. Borden, MD, has assembled a multidisciplinary team of established and emerging leaders to detail the clinical problems and factors influencing the therapeutic deployment of these biologicals. Throughout, the focus is on providing the rationale and background by which the many promising biologically targeted therapies are translated via clinical trials into effective new therapies. Among the interventional agents treated are cytokines, monoclonal antibodies, targeted inhibitors, cellular therapies, and angiogenesis inhibitors. Special attention is given to adjuvant therapies for melanoma in patients staged as being at high risk for recurrence. These therapies include interferons, vaccines aimed at stimulating T cell response, and therapies targeted at abnormal melanoma cell proliferative signaling and angiogenesis inhibitors. Among the cutting-edge therapies discussed are novel cytokines that influence dendritic NK and T cell function, an allogenic cellular extract vaccine, and new targets (NF-kB and IL-8) for antiangiogenesis therapies. State-of-the-art and forward looking, Melanoma: Biologically Targeted Therapeutics critically evaluates the biological, cellular, and targeted therapies that are already reducing mortality from primary melanomas, and are expected increasingly to continue so for the foreseeable future.
|
| Subject
|
:
|
Biological products-- Therapeutic use.
|
| Subject
|
:
|
Medicine.
|
| Subject
|
:
|
Melanoma-- Immunotherapy.
|
| Subject
|
:
|
Oncology.
|
| Subject
|
:
|
Proteins-- Therapeutic use.
|
| Subject
|
:
|
Biological products-- Therapeutic use.
|
| Subject
|
:
|
Medicine.
|
| Subject
|
:
|
Oncology.
|
| Subject
|
:
|
Proteins-- Therapeutic use.
|
| Dewey Classification
|
:
|
616.99/47706
|
| LC Classification
|
:
|
RC254-282
|
| Added Entry
|
:
|
Borden, Ernest C.
|
| |